Faculty and Disclosures

Faculty:

Sophie J. Bakri, MD
Program Chair
Professor of Ophthalmology
Mayo Clinic
Rochester, Minnesota

Peter K. Kaiser, MD
Chaney Family Endowed Chair of Ophthalmology Research
Cole Eye Institute
Cleveland, Ohio

Baruch D. Kuppermann, MD, PhD
Roger F. Steinert Professor and Chair
Department of Ophthalmology
School of Medicine
Director, Gavin Herbert Eye Institute
Professor, Department of Biomedical Engineering
The Henry Samueli School of Engineering
University of California, Irvine
Irvine, California

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Sophie J. Bakri, MD, and/or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Advernum, Alimera Sciences, Allegro, Allergan, EyePoint, Kala Pharmaceuticals, Oxurion, Novartis, and Roche.  Grant/Research Support: Lowy Medical Foundation and NIH.

Peter Kaiser, MD, and/or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie, Aerpio, Alcon, Allegro Ophthalmics, Allergan, Bayer, Bausch + Lomb, Biogen Idec, Boerenger Ingelheim, Clearside Biomedical, Eyevensys, Galecto, Galimedix, iRenix, jCyte,Kanghong Biotech, Kodiak Sciences, NGM Biopharmaceuticals, Novartis, Omeros, Ophthea, Ophthotech, Oxurion, Regeneron Pharmaceuticals, RegenexBio, Retinal Sciences, Santen, SciFluor, Shire, Stealth Biotherapeutics, and Verena. Grant/Research Support: National Eye Institute, National institute of Health and Research to Prevent Blindness. Speaker’s Bureau: Allegro Ophthalmics, Clearside Biomedical, Ophthotech, Retinal Sciences and Verena.

Baruch D. Kuppermann, MD, PHD, and/or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allegro, Allergan, Aprea, Cell Care, Dose, Eyedaptic, Galimedix, Genentech, Glaukos, Interface Biologics, IVERIC bio/Ophthotech,  jCyte, Novartis, Oculis, Regeneron, Revana, Ripple Therapeutics, and Theravance Biopharma. Grants/Research Support: Alcon, Allegro, Allergan, Apellis, Clearside, Genentech, GSK, Ionis, IVERIC bio, jCyte, Novartis, and Regeneron.

Christina Y. Weng, MD, MBA, and/or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, Alimera Sciences, Allergan and Novartis.

The Evolve staff and planners have no financial relationships with commercial interests.

Nisha Mukherjee, MD, peer reviewer, have no financial relationships with commercial interests.

Disclaimer

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Allergan.